[Is adjuvant chemotherapy of colon cancers (Dukes C; TxN+) regarded as standard today?].
Farthmann
E
E
Chirurgische Universitätsklinik, Freiburg.
Herfarth
C
C
Laffer
U
U
Harder
F
F
Schlag
P M
PM
Wilke
H
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage / Q000009:adverse effects; D009367:Neoplasm Staging; D015996:Survival Rate
D007978:Levamisole; D005472:Fluorouracil
Ist die adjuvante Chemotherapie von Kolonkarzinomen (Dukes C; TxN+) heute als Standard anzusehen?